Compared side by side

Tirzepatide vs VK2735: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

Both are weekly shots that switch on the same two receptors, GLP-1 and GIP: tirzepatide was the first such dual agonist, and VK2735, from Viking Therapeutics, takes the same approach and is also being tested as a daily tablet. Tirzepatide is FDA-approved, as Mounjaro and Zepbound; VK2735 has been in phase 3 since June 2025 and isn’t approved anywhere. In its 13-week phase 2 trial, people on VK2735 lost about 9% to 15% of their body weight depending on the dose, and tirzepatide’s 15 mg produced up to 22.5% at 72 weeks (SURMOUNT-1).

Side by side

ComparedTirzepatideVK2735
CategoryMetabolic & GLP-1Metabolic & GLP-1
Also known asMounjaro, Zepbound, LY3298176VK-2735, VK 2735
What it isThe first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks).A weekly GLP-1 and GIP dual agonist from Viking Therapeutics, the same two-receptor approach as tirzepatide, also being tested as a daily tablet.
How it worksDual GIP/GLP-1 receptor agonist. Significantly reduces body weight through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. Approved for T2DM and obesity management.Once-weekly peptide that switches on both the GLP-1 and the GIP receptors, the same pair tirzepatide works through. A side chain stretches its half-life to about 7 to 10 days in people, long enough for weekly shots. The idea is the one tirzepatide proved: two incretin signals that curb appetite and food intake together. Viking also makes it as a daily tablet, the same molecule by mouth. Investigational, in phase 3 since June 2025.
Commonly reportedVery strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound).In trials, nausea and other GI effects early on, fading as the dose holds. It is in phase 3 and not approved anywhere.
Studied rangeFDA label: 2.5–15 mg, starting dose 2.5 mg.Research range: 2.5–17.5 mg, starting dose 2.5 mg. Studied in research — not a recommendation.
How oftenWeeklyWeekly
Half-life~5 days (FDA label)~9 days (measured in people: 170–250 hours after single doses, Viking phase 1, 2023)
RouteSubQ injectionSubQ injection
Typical runFDA-approved for ongoing use. Titrate slowly upward. Community maintains on minimum effective dose.Used continuously, once weekly, in its trials: 13 weeks in phase 2 and 78 weeks in phase 3. In Viking's maintenance study, people who switched after 21 weekly doses to a shot every other week or once a month kept most of their loss over the next 12 weeks; on placebo they kept about 61%.
EvidenceEstablished: clinical trials or FDA-approved use existsModerate: animal studies + some human data
Common side effectsNausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigueNausea, constipation, diarrhea, vomiting, acid reflux, fatigue, dry mouth

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Taking tirzepatide or VK2735? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

Tirzepatide

  • Day 1–28 · 2.5 mg Getting your gut acclimated
  • Day 29–56 · 5 mg First therapeutic dose — weight drops
  • Day 57–112 · 7.5 mg Dual agonism in full effect
  • Day 113–168 · 12.5 mg Max titration reached
  • Day 169–504 Weeks 24 to 72: where most people plateau
  • Day 365+ A maintenance medication, not a course

Every card for tirzepatide, with its sources

VK2735

  • Day 1–21 · 2.5 mg Low start, first weeks
  • Day 22–91 The first 13 weeks
  • Day 22–546 · 7.5 mg The lowest phase 3 dose
  • Day 43–546 · 12.5 mg The middle phase 3 dose
  • Day 43–546 · 17.5 mg The top phase 3 dose
  • Day 150+ Holding the loss on fewer shots

Every card for VK2735, with its sources

Questions people ask

How long do tirzepatide and VK2735 last?

The half-life of tirzepatide is ~5 days (FDA label). The half-life of VK2735 is ~9 days (measured in people: 170–250 hours after single doses, Viking phase 1, 2023).

How often are tirzepatide and VK2735 taken?

Tirzepatide: weekly. Route: SubQ injection. VK2735: weekly. Route: SubQ injection.

How are tirzepatide and VK2735 dosed in research?

The FDA label range for tirzepatide is 2.5–15 mg, with a 2.5 mg starting dose. The research range for VK2735 is 2.5–17.5 mg, with a 2.5 mg starting dose. Studied in research — not a recommendation.

What are the common side effects of tirzepatide and VK2735?

For tirzepatide, the library lists: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue. For VK2735: nausea, constipation, diarrhea, vomiting, acid reflux, fatigue, dry mouth.

Each one in full

Track it in the app

PepVault for iPhone

Taking tirzepatide or VK2735? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo